Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Benda Begins to Deal with Upcoming Financial Problem

publication date: Jan 14, 2008

Benda Pharmaceutical announced that it has begun to explore strategic alternatives, having signed up CRT Capital Group LLC to assist the company. They will explore M&A, joint venture, divestiture, spin-off, financing or other capital market transactions. Benda announced at the same time that it would seek to move its listing to the American Exchange. Benda has good reason to seek an AMEX listing. More details...

Stock Symbols: (OTCBB: BPMA) (NYSE: AOB)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital